← All trials
NCT05192213
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Dec 20, 2023
- First posted
- Jan 14, 2022
- Last posted
- Jan 14, 2022
- Enrollment
- 1090
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital Sirio-LibanesLead sponsor
- Hospital Sirio-LibanesOverall official - principal investigator
- Government of BrazilCollaborator
- Hospital Sirio-LibanesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.